I needed to give this thing a name

Written by

in

I needed to know what was wrong with me. Not just for me, but for Dad too. He’d lived for years with a muscular dystrophy that nobody had ever managed to identify. He died without knowing what it was.

Now it seemed increasingly likely that whatever he’d had, I had too. I needed to be able to give this thing a name. Because once something has a name, you can start to make plans.

Something was wrong

On 25 April 2017, a blood test showed that my creatine kinase — or CK — level was 728, more than twice the top of the normal range shown on the test.

CK is an enzyme found predominantly in muscle, and an elevated level can be a sign that muscle is being damaged.

That result was the beginning of a journey that would take more than six years. Initially, things seemed to move reasonably quickly. I saw neurologists. I had nerve conduction tests and an EMG. I had a muscle biopsy.

There was clearly something going on with my muscles. The biopsy result was non-specific myopathy. In other words: yes, you have a muscle disease. Which one? We don’t know.

Bouncing around the system

Over the following years I bounced between a lot of different medical professionals. There wasn’t much continuity and, from my perspective, there wasn’t much progress either.

I saw some very good people. But I also reached the limits of what individual specialists knew. More than once, somebody effectively told me:

“I’ve reached the limit of my knowledge. I don’t know where to take this.”

Eventually I was advised to leave the private medical system and get myself properly back into the NHS. For something unusual like this, I was told, that’s where the people with the really specialist knowledge were. It turned out to be good advice. But it also meant waiting.

FSHD had been tested for before

One of the confusing things about the journey was that I’d already undergone testing for FSHD and hadn’t received a diagnosis from it.

So FSHD could quite reasonably appear to have been explored already. What eventually mattered was that the earlier testing hadn’t identified FSHD Type 2.

That distinction would turn out to matter rather a lot.

Not knowing had consequences

In the meantime, I had to live with not knowing what was happening to my body. And that affected the decisions I made.

Specialists were understandably cautious about exercise. Until they knew what was causing the problems with my muscles, there was concern that vigorous exercise might make things worse. So I stopped.

Running had previously been a huge part of my life. Hayley and I had run 10Ks, trail races and half marathons. We’d run through countryside with the dogs. We’d run in sunshine, rain, snow and hail. We’d run when we went on holiday.

Now I wasn’t running at all. As the years passed, I lost fitness. I lost strength. And I gained around 20kg.

Looking back, that’s one of the things I find hardest about how long the diagnosis took.

If I’d known, I could have carried on doing the thing I loved — running — in moderation, and kept myself fit. Not knowing didn’t protect me from my condition. In some ways, it made dealing with it harder.

Then I went to Newcastle

FSHD had been considered before, but it still hadn’t led us to an answer. Then, in October 2022, I found myself back in Newcastle at another specialist clinic.

The doctor I met that day is someone I have great respect for, so I’m not going to name him here. I remember walking into the consulting room.

He looked at me. He turned and whispered something to a colleague. And within what seemed like moments, FSHD was back on the table very firmly.

The letter from that appointment, dated 6 October 2022, still described me as having an “adult onset undiagnosed myopathy.” But further down it said:

“We suspect FSHD as one potential option and we have requested the genetic test.”

That was different. This time, the suspicion was concrete enough to trigger the testing that would finally give me the answer.

But I wasn’t celebrating yet

You might imagine that I walked out of that appointment convinced we’d cracked it. I didn’t. There had been too many assumptions by then.

Too many possibilities. Too many wrong turns.

I’d spent years thinking that the next test, the next specialist or the next investigation might finally give us the answer. So even though this felt different, I wasn’t prepared to believe we’d reached the end until somebody could prove it.

The blood sample for the genetic investigation was received just before Christmas 2022. Then there was more waiting. Testing for FSHD1 still didn’t provide the answer. But this time they kept looking.

In May 2023, genetic testing identified a change in a gene called SMCHD1. That led to another specialist test looking at something called D4Z4 methylation. I won’t attempt to explain all of that here. That’s another article. The important bit is what happened next.

16.9%

The final genetics report contains a number that now means rather a lot to me. 16.9%. That was my average D4Z4/DR1 methylation result. The report described it as severe hypomethylation.

And immediately underneath came the words I’d been looking for since 2017:

“Consistent with a diagnosis of FSHD2.”

There it was.

Facioscapulohumeral muscular dystrophy Type 2. FSHD2.

It had a name.

Just tell me

The phone call came from the specialist in June 2023. I was offered the opportunity to come into clinic and talk through the results, or they could tell me over the phone. There was no decision to make.

I’d already waited more than six years. I was in a hurry.

I wanted the answer right now.

So they told me. FSHD Type 2. I was elated. I was relieved.

And, if I’m honest, I was frustrated too.

Because after all those years of searching, we’d finally arrived at an answer that somebody familiar with FSHD had suspected within minutes of meeting me.

But mostly, I finally knew.

It had a name

I immediately started reading. I’d accumulated information over the years about various conditions that might explain what was happening to me. I got rid of it. I didn’t need to read about all the things I might have anymore.

For the first time, I had focus. I could learn about FSHD. I could understand what it might mean for me. I could find the people who knew about it. I could think about exercise again. I could start making decisions about how I wanted to live with it.

And there was something else. Dad had died in 2011 without ever knowing the name of the muscular dystrophy he’d lived with. I can’t retrospectively diagnose him from my own genetic test. But I knew what this result meant to me.

For more than six years I’d been searching for an answer for myself. In some ways, I’d been searching for one for Dad for much longer than that. Now, finally, this thing had a name.

Once something has a name, you can start to make plans.